

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0998D3Serial No.
09/705,457

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Andya et al.

Filing Date

02 Nov 2000

Group

1644

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
1149	209 4,753,894	28.06.88	Frankel et al.			
	210 4,935,341	19.06.90	Bargmann et al.			
	211 4,943,533	24.07.90	Mendelsohn et al.			
	212 4,968,603	06.11.90	Slamon et al.			
	213 4,975,278	04.12.90	Senter et al.			
	214 5,169,774	08.12.92	Frankel et al.			
	215 5,183,884	02.02.93	Kraus et al.			
	216 5,288,477	22.02.94	Bacus, S.			
	217 5,359,046	25.10.94	Capon et al.			
	218 5,367,060	22.11.94	Vandlen et al.			
	219 5,401,638	28.03.95	Carney et al.			
	220 5,464,751	07.11.95	Greene et al.			
	221 5,480,968	02.01.96	Kraus et al.			
	222 5,578,482	26.11.96	Lippman et al.			
	223 5,604,107	18.02.97	Carney et al.			
	224 5,641,869	24.06.97	Vandlen et al.			
	225 5,654,403	05.08.97	Smith et al.			
	226 5,663,144	02.09.97	Greene et al.			
	227 5,677,171	14.10.97	Hudziak et al.			
	228 5,705,157	06.01.98	Greene, M. L.			
	229 5,720,937	24.02.98	Hudziak et al.			
	230 5,720,954	24.02.98	Hudziak et al.			
	231 5,726,023	10.03.98	Cheever et al.			
	232 5,728,687	17.03.98	Bissery, M.			
	233 5,747,261	05.05.98	King et al.			
	234 5,770,195	23.06.98	Hudziak et al.			
	235 5,772,997	30.06.98	Hudziak et al.			
	236 5,776,427	07.07.98	Thorpe et al.			
	237 5,783,186	21.07.98	Arakawa et al.			
	238 5,792,838	11.08.98	Smith et al.			
	239 5,801,005	01.09.98	Cheever et al.			
	240 5,824,311	20.10.98	Greene et al.			
	241 5,834,229	10.11.98	Vandlen et al.			
	242 5,837,243	17.11.98	Deo et al.			
	243 5,837,523	17.11.98	Greene et al.			
	244 5,840,525	24.11.98	Vandlen et al.			

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P0998D3Serial No.
09/705,457

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Andya et al.

Filing Date

02 Nov 2000

Group

1644

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
MO	245 5,846,538	08.12.98	Cheever et al.			
	246 5,856,110	05.01.99	Vandlen et al.			
	247 5,859,206	12.01.99	Vandlen et al.			
	248 5,869,445	09.02.99	Cheever et al.			
	249 5,876,712	02.03.99	Cheever et al.			
	250 5,877,305	02.03.99	Huston et al.			
	251 5,908,835	01.06.99	Bissery, M.			
	252 5,910,486	08.06.99	Curriel et al.			
	253 5,922,845	13.07.99	Deo et al.			
	254 5,939,531	17.08.99	Wels et al.			
	255 5,977,322	02.11.99	Marks et al.			
	256 5,985,553	16.11.99	King et al.			
	257 6,015,567	18.01.00	Hudziak et al.			
	258 6,028,059	22.02.00	Curriel et al.			
	259 6,054,297	25.04.00	Carter et al.			
	260 6,054,561	25.04.00	Ring, D. B.			
	261 6,080,429	27.06.00	Cleland et al.			
	262 6,123,939	26.09.00	Shawver et al.			
	263 6,165,464	26.12.00	Hudziak et al.			
	264 6,267,958	31.07.01	Andya et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
MO	265 0,599,274 A1	01.06.94	EPO			
	266 0,711,565 B1	26.08.98 15.05.96	EPO			
	267 0,16,812 A1	28.09.94	EPO			
	268 WO 92/10573	25.06.92	PCT			
	269 WO 93/12220	24.06.93	PCT			
	270 WO 93/21232	28.10.93	PCT			
	271 WO 93/21319	28.10.93	PCT			
	272 WO 94/00136	06.01.94	PCT			
	273 WO 94/10202	11.05.94	PCT			
	274 WO 94/22478	13.10.94	PCT			
	275 WO 94/28127	08.12.94	PCT			
	276 WO 95/16051	15.06.95	PCT			
	277 WO 95/17507	29.06.95	PCT			

Examiner

Mariano Del

Date Considered

10/17/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449			U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3		Serial No. 09/705,457		
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)						Applicant Andya et al.			
						Filing Date 02 Nov 2000		Group 1644	
FOREIGN PATENT DOCUMENTS									
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No		
MD ↓ MD	278	WO 95/28485	26.10.95	PCT	X	X	X	X	
	279	WO 96/18409	20.06.96	PCT					
	280	WO 96/30046	03.10.96	PCT					
	281	WO 97/20858	12.06.97	PCT					
	282	WO 97/27848	07.08.97	PCT					
	283	WO 97/38731	23.10.97	PCT					
	284	WO 97/45140	04.12.97	PCT					
MD	285	WO 98/45479	15.10.98	PCT					
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)									
MD	286	Burton et al., "Lyophilized hyperimmune equine serum as a source of antibodies for neonatal foals" <u>American Journal of Veterinary Research</u> 42(2):308-310 (Feb 1981)							
MD	287	Cleland et al., "Development of Stable Protein Formulations for Microencapsulation in Biodegradable Polymers" <u>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</u> 22:514-515 (1995)							
MD	288	Natali et al., "Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues" <u>International Journal of Cancer</u> 45(3):457-461 (Mar 15, 1990)							
MD	289	Press et al., "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissue" <u>Oncogene</u> 5:953-962 (1990)							
	290	Valone et al., "Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu" <u>Journal of Hematotherapy</u> 4(5):471-475 (Oct 1995)							
Examiner					Date Considered 10/17/03				
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.
P0998D3

Serial No.
09/705,457

LIST OF DISCLOSURES CITED BY APPLICANT

























(Use several sheets if necessary)

Applicant
Andya et al.


Filing Date
02 Nov 2000

Group
1644

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	291	5,449,760	12.09.95	Chang			
	292	5,543,144	06.08.96	Chang, T.			
	293	5,614,611	25.03.97	Chang, T.			
	294	5,994,514	30.11.99	Jardieu et al.			
	295	6,037,453	14.03.00	Jardieu et al.			
	296	6,329,509	11.12.01	Jardieu et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	297	407,392	28.10.98	EPO				
	298	WO 95/11009	27.04.95	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P0998D3	Serial No. 09/705,457
		Applicant Andya et al.	
		Filing Date 02 Nov 2000	Group 1649 To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	No
	70 WO 93/04173	04.03.93	PCT				
	* 71 WO 93/05799	01.04.93	PCT				
	72 WO 93/19197	30.09.93	PCT				
	73 WO 95/15977	15.06.95	PCT				
	74 WO 97/04807	13.02.97	PCT				
	75 WO 97/10004	20.03.97	PCT				
	76 WO 97/33616	18.09.97	PCT				
	* 77 WO 98/22136	28.05.98	PCT				
	78 WO 99/01556	14.01.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	* 79	Arakawa et al., "Protein-Solvent Interactions in Pharmaceutical Formulations" <u>Pharmaceutical Research</u> 8(3):285-291 (1991)
MB	80	Bam et al., "Stability of Protein Formulations: Investigation of Surfactant Effects by a Novel EPR Spectroscopic Technique" <u>Pharm. Res.</u> 12:2-11 (1995)
MB	81	Baniyash et al., "Anti-IgE monoclonal antibodies directed at the Fc _ε receptor binding site" <u>Molecular Immunology</u> 25(8):705-711 (1988)
MB	82	Baniyash et al., "Inhibition of IgE Binding to Mast Cells and Basophils by Monoclonal Antibodies to Murine IgE" <u>European Journal of Immunology</u> 14:799-807 (1984)
	* 83	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)
	* 84	Beauvais et al., "Both Glassy State and Native Structure are Required for Storage Stability of Lyophilized Interleukin-1 Receptor Antagonist" <u>Pharm. Res.</u> (Abstract #2007) 12(9):S-80 (1995)
MB	85	Berglund et al., "Spirometric studies in normal subjects" <u>Acta. Med. Scand.</u> 173:185-192 (1963)
MB	86	Blank et al., "Characterization of Truncated α Chain Products from Human, Rat, and Mouse High Affinity Receptor for Immunoglobulin E" <u>Journal of Biological Chemistry</u> 266(4):2639-2646 (February 5, 1991)
	* 87	Boulet et al., "Inhibitory Effects of an Anti-IgE Antibody E25 on Allergen-induced Early Asthmatic Response" <u>Am J Respir Crit Care Med</u> 155:1835-1840 (1997)
MB	88	Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984)
MB	89	Bozelka et al., "Effects of Anti-ε on Total and Specific IgE Levels in Adult Mice" <u>Int. Archs. Allergy Appl. Immun.</u> 78:51-56 (1985)
MB	90	Bozelka et al., "IgE isotype suppression in anti-ε-treated mice" <u>Immunology</u> 46:527-532 (1982)
MB	91	Brown et al., "Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival" <u>Proc. Natl. Acad. Sci. USA</u> 88:2663-2667 (April 1991)
MB	92	Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue" <u>Journal of Cell Biology</u> 111:2129-2138 (1990)

Examiner


Date Considered


*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)			Applicant Andya et al.	
			Filing Date 02 Nov 2000	Group To Be Assigned 1644
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
MD	93	Burrows et al., "Association of asthma with serum IgE levels and skin-test reactivity to allergens" <u>New England J. of Medicine</u> 320(5):271-277 (Feb. 2, 1989)		
MD	94	Burt et al., "Analysis of the interaction between rat immunoglobulin E and rat mast cells using anti-peptide antibodies" <u>Molecular Immunology</u> 24(4):379-389 (1987)		
MD	95	Burt et al., "Inhibition of binding of rat IgE to rat mast cells by synthetic IgE peptides" <u>European Journal of Immunology</u> 17:437-440 (1987)		
MD	* 96	Chang and Fischer, "Development of an Efficient Single-Step Freeze-Drying Cycle for Protein Formulations" <u>Pharm. Res.</u> 12(6):831-837 (1995)		
MD	* 97	Chang et al., "Development of a Stable Freeze-dried Formulation of Recombinant Human Interleukin-1 Receptor Antagonist" <u>Pharmaceutical Research</u> 13(2):243-248 (1996)		
MD	98	Chang et al., "Monoclonal Antibodies Specific for Human IgE-producing B Cells: A Potential Therapeutic for IgE-mediated Allergic Diseases" <u>Bio/Technology</u> 8:122-126 (February 1990)		
MD	* 99	Cleland and Jones, "Development of Stable Protein Formulations for Microencapsulation in Biodegradable Polymers" <u>Proceed. Intern. Symp. Control. Rel. Biogact. Mater.</u> 22:514-515 (1995).		
MD	* 100	Cleland et al., "The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation" <u>Critical Reviews in Therapeutic Drug Carrier Systems</u> 10(4):307-377 (1993)		
MD	101	Co et al., "Humanized antibodies for antiviral therapy" <u>Proc. Natl. Acad. Sci. USA</u> 88:2869-2873 (April 1991)		
MD	102	Cockcroft et al., "Allergen-induced increase in non-allergic bronchial reactivity" <u>Clinical Allergy</u> 7:503-513 (1977)		
MD	103	Cockcroft et al., "Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine" <u>J. Allergy Clin. Immunol.</u> 79(5):734-740 (May 1987)		
MD	104	Cockcroft et al., "Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine" <u>Am. Rev. Respir. Dis.</u> 135:264-267 (1987)		
MD	105	Cockcroft et al., "rhMAB-E25 (E25), Humanized Murine Monoclonal Anti-IgE, Inhibits the Allergen-induced Early Asthmatic Response (EAR)" <u>J. of Allergy and Clinical Immunology</u> (Abstract no. 532) 97(1 Part III):315 (January 1996)		
MD	106	Cohn et al., "Induction of Airway Mucus Production By T Helper 2 (Th2) Cells: A Critical Role for Interleukin 4 In Cell Recruitment But Not Mucus Production" <u>Journal of Experimental Medicine</u> 186(10):1737-1747 (November 17, 1997)		
MD	107	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , Reisfeld et al., New York:Alan R. Liss, Inc. pps. 77-96 (1985)		
MD	108	Conrad et al., "The Interaction of Human and Rodent IgE with the Human Basophil IgE Receptor" <u>J. of Immunology</u> 130(1):327-333 (1983)		
MD	109	Conrad, D.H., "FcεRII/CD23: The low affinity receptor for IgE" <u>Ann. Rev. Immunol.</u> 8:623-639 (1990)		
MD	110	Corrigan et al., "T Cells and Eosinophils in the Pathogenesis of Asthma" <u>Immunology Today</u> 13(12):501-507 (1992)		
MD	111	Coyle et al., "Central Role of Immunoglobulin (Ig) E in the Induction of Lung Eosinophil Infiltration and T Helper 2 Cell Cytokine Production: Inhibition by a Non-anaphylactogenic Anti-IgE Antibody" <u>Journal of Experimental Medicine</u> 183:1303-1310 (April 1996)		
MD	112	Crescioli et al., "Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects" <u>Ann. Allergy</u> 66:245-251 (March 1991)		
Examiner			Date Considered	
			10/14/00	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.	
				Filing Date 02 Nov 2000	Group <u>1644</u> Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
<u>NO</u>	113	Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins" <u>Nucleic Acids Research</u> 19(9):2471-2476 (May 11, 1991)			
<u>NO</u>	114	Deisenhofer, J., "Crystallographic Refinement and Atomic Models of a Human Fc Fragment and its complex with Fragment B of Protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution" <u>Biochemistry</u> 20(9):2361-2370 (April 28, 1981)			
<u>NO</u>	115	Diaz et al., "Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions" <u>Am. Rev. Respir. Dis.</u> 139:1383-1389 (1989)			
<u>NO</u>	116	Dodge et al., "The prevalence and incidence of asthma and asthma-like symptoms in a general population sample" <u>Am. Rev. Respir. Dis.</u> 122:567-575 (1980)			
	*117	Draber et al., "Stability of Monoclonal IgM Antibodies Freeze-Dried in the Presence of Trehalose" <u>Journal of Immunological Methods</u> 181(1):37-43 (1995)			
<u>NO</u>	118	Duncan et al., "Localization of the binding site for the human high-affinity FC receptor on IgG" <u>Nature</u> 332:563-564 (April 7, 1988)			
<u>NO</u>	119	Fahy et al., "Analysis of cellular and biochemical constituents of induced sputum after allergen challenge: A method for studying allergic airway inflammation" <u>J. Allergy Clin. Immunol.</u> 93(6):1031-1039 (June 1994)			
<u>NO</u>	120	Fahy et al., "Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects" <u>Am. Rev. Respir. Dis.</u> 147:1126-1131 (1993)			
	*121	Fahy et al., "The Effect of an Anti-IgE Monoclonal Antibody on the Early- and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects" <u>Am J Respir Crit Care Med</u> 155:1828-1834 (1997)			
<u>NO</u>	122	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)			
<u>NO</u>	123	Fick et al., "Bronchoalveolar Lavage in Allergic Asthmatics" <u>Am. Rev. Respir. Dis.</u> 135:1204-1209 (1987)			
<u>NO</u>	124	Fick et al., "Increased bronchovascular permeability after allergen exposure in sensitive asthmatics" <u>J. Appl. Physiol.</u> 63(3):1147-1155 (1987)			
<u>NO</u>	125	Fisher et al., "Biostatistics: a methodology for the health sciences", New York: John Wiley & Sons pps. 861-862 (1993)			
<u>NO</u>	126	Froehlich et al., "Multiple Doses of a Recombinant Humanized Monoclonal Anti IgE Antibody Are Safely Tolerated and Decrease Free Serum IgE to Undetectable Levels" <u>J. Allergy and Clinical Immunology</u> (Abstract #863) 95(1 Part II):356 (January 1995)			
<u>NO</u>	127	Geha et al., "IgE sites relevant for binding to type 1 Fc epsilon (FCER) receptors on mast cells" <u>J. Allergy & Clin. Immunol.</u> (Abstract No. 20) 79(1):129 (1987)			
<u>NO</u>	128	Glennie et al., "Preparation and Performance of Bispecific F(ab') ₂ Antibody Containing Thioether-Linked Fab'γ Fragments" <u>J. Immunol.</u> 139(7):2367-2375 (October 1, 1987)			
<u>NO</u>	129	Gonzalez et al., "Allergen-Induced Recruitment of Bronchoalveolar Helper (OKT4) and Suppressor (OKT8) T-Cells in Asthma" <u>Am. Rev. Respir. Dis.</u> 136:600-604 (1987)			
<u>NO</u>	130	Gorman et al., "Reshaping a therapeutic CD4 antibody" <u>Proc. Natl. Acad. Sci. USA</u> 88(10):4181-4185 (May 15, 1991)			
<u>NO</u>	131	Grammer et al., "Diagnosis and classification of asthma" <u>Chest</u> 101(6):393S-395S (June 1992)			
<u>NO</u>	132	Gundel et al., "Endothelial Leukocyte Adhesion Molecule-1 Mediates Antigen-Induced Acute Airway Inflammation and Late-Phase Airway Obstruction in Monkeys" <u>J. Clin. Invest.</u> 88:1407-1411 (October 1991)			
Examiner		<u>Marianne</u>		Date Considered <u>10/14/03</u>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.	
				Filing Date 02 Nov 2000	Group To Be Assigned <i>1644</i>
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
<i>WSD</i>	133	Haak-Frendscho et al., "Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo" <u>Immunology</u> 82:306-313 (1994)			
<i>WSD</i>	134	Hakimi et al., "The α subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding" <u>Journal of Biological Chemistry</u> 265(36):22079-22081 (1990)			
<i>WSD</i>	135	Hammerling et al., "Production of Antibody-Producing Hybridomas in the Rodent Systems" <u>Monoclonal Antibodies and T-Cell Hybridomas</u> , New York:Elsevier, Chapter 12, pps. 563-587 (1981)			
<i>WSD</i>	136	Hargreave, F.E., "Late-phase asthmatic responses and airway inflammation" <u>J. Allergy Clin. Immunol.</u> 83(2):525-527 (February 1989)			
<i>WSD</i>	137	Helm et al., "Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ϵ -chain fragment of 76 amino acids" <u>Proc. Natl. Acad. Sci.</u> 86:9465-9469 (December 1989)			
<i>WSD</i>	138	Helm et al., "The mast cell binding site on human immunoglobulin E" <u>Nature</u> 331:180-183 (January 14, 1988)			
<i>WSD</i>	139	Hoffman, D. R., "Enzyme-linked immunosorbent assays (ELISA) for immunoglobulin E and blocking antibodies" <u>Methods in Enzymology</u> , Chapter 45, 73:656-666 (1981)			
<i>WSD</i>	140	Hook et al., "Monoclonal Antibodies Defining Epitopes on Human IgE" <u>Molecular Immunology</u> 28(6):631-639 (1991)			
<i>WSD</i>	141	Hook et al., "Monoclonal antibodies defining epitopes on IgE" <u>Federation of American Societies for Experimental Biology</u> (71st Annual Meeting, Abstract #6008) pps. 1346 (1987)			
<i>WSD</i>	142	Hook et al., "Monoclonal antibodies to human IgE" <u>Federation Proceedings</u> (Abstract No. 4177 Only) 40(3):968 (1994)			
	143	"Immune Globulin Intravenous (Human) Sandoglobulin" Product Information, Physicians' Desk Reference pps. 2075-2077 (1994)			
<i>WSD</i>	144	Ishizaka, K., "Immunoglobulin E (IgE)" <u>Methods in Enzymology</u> 116(Part II):76-94 (1985)			
	145	"IVEEGAM", "Product Information, IMMUNO-U.S., Inc." pps. 2 pages (1992)			
	146	Izutsu et al., "The effects of additives on the stability of freeze-dried β-galactosidase stored at elevated temperature" <u>Intl. J. Pharmaceutics</u> 71:137-146 (1991)			
<i>WSD</i>	147	Jaffers et al., "Monoclonal Antibody Therapy, Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression" <u>Transplantation</u> 41(5):572-578 (May 1986)			
<i>WSD</i>	148	Jefferis et al., "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFc γ R)" <u>Molecular Immunology</u> 27(12):1237-1240 (1990)			
<i>WSD</i>	149	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)			
<i>WSD</i>	150	Junghans et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders" <u>Cancer Research</u> 50(5):1495-1502 (March 1, 1990)			
<i>WSD</i>	151	Kabat <u>Sequences of Proteins of Immunological Interest</u> (pgs. 662-663, 671-672, 680-681, 697, 701-702, 710, 719-720, 2275-2276), 5th edition 1 (1991)			
<i>WSD</i>	152	Kabat <u>Sequences of Proteins of Immunological Interest</u> , 4th edition pps. 41-42, 167-168 (1987)			
Examiner		<i>Maiana R</i>		Date Considered <i>10/14/03</i>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.	
				Filing Date 02 Nov 2000	Group 1644 To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
153	Kay et al., "Mediators of Hypersensitivity and Inflammatory Cells in Early- and Late-Phase Asthmatic Reactions" <u>Asthma: Physiology, Immunopharmacology and Treatment (3rd Int'l Symposium)</u> (Chp. 13), Kay et al., New York:Academic Press pps. 211-227 (1984)				
154	Kohler et al., "Derivation of Specific Antibody-producing Tissue Culture and Tumor Lines by Cell Fusion" <u>European Journal of Immunology</u> 6:511-519 (1976)				
155	Korsgren et al., "Allergic Eosinophil-rich Inflammation Develops in Lungs and Airways of B Cell-deficient Mice" <u>Journal of Experimental Medicine</u> 185(5):885-892 (March 1997)				
156	Kulczycki et al., "The Interaction of IgE with Rat Basophilic Leukemia Cells, Evidence for Specific Binding of IgE" <u>Journal of Experimental Medicine</u> 139:600-616 (1974)				
157	Kurokawa et al., "Expression of human immunoglobulin E ϵ chain cDNA in E. coli" <u>Nucleic Acids Research</u> 11(10):3077-3085 (1983)				
158	Larsen et al., "An Animal Model of the Late Asthmatic Response to Antigen Challenge" <u>Asthma: Physiology, Immunopharmacology and Treatment (3rd Int'l Symposium)</u> (Chp. 15), Kay et al., New York:Academic Press pps. 245-262 (1984)				
159	Lazar et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities" <u>Molecular & Cellular Biology</u> 8(3):1247-1252 (Mar. 1988)				
160	Liu et al., "Expression of a biologically active fragment of human IgE ϵ chain in Escherichia coli" <u>Proc. Natl. Acad. Sci.</u> 81:5369-5373 (September 1984)				
	Manning et al., "Stability of Protein Pharmaceuticals" <u>Pharm. Res.</u> 6(11):903-918 (1989)				
*161					
162	Marsh et al., "Increases in Airway Reactivity to Histamine and Inflammatory Cells in Bronchoalveolar Lavage after the Late Asthmatic Response in an Animal Model" <u>Am. Rev. Respir. Dis.</u> 131:875-879 (1985)				
163	Metzger et al., "How Antibodies Work: Focus on Fc Receptors" <u>FASEB J.</u> 2(1):3-11 (January 1988)				
164	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)				
165	Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985)				
166	Murray et al., "Dust-Free Bedrooms in the Treatment of Asthmatic Children with House Dust or House Dust Mite Allergy: A Controlled Trial" <u>Pediatrics</u> 71(3):418-422 (March 1983)				
167	Nakajima et al., "CD4 ⁺ T-Lymphocytes and Interleukin-5 Mediate Antigen-induced Eosinophil Infiltration into the Mouse Trachea" <u>Am. Rev. Respir. Dis.</u> 146:374-377 (1992)				
168	Nakajima et al., "Effect of Saiboku-to (TJ-96) on Bronchial Asthma" <u>Annals of the New York Academy of Sciences</u> 685:549-560 (June 23, 1993)				
169	Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function" <u>Nature</u> 314:268-270 (March 21, 1985)				
170	Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984)				
171	Neurath, A. R., "Use of ¹²⁵ I-labeled anti-2,4-dinitrophenyl (DNP) antibodies as a general tracer in solid-phase radioimmunoassays" <u>Methods in Enzymology</u> 73:127-138 (1981)				
*172	Nielsen, et al., "Stability of Freeze Dried Horseradish Peroxidase Conjugated Monoclonal Antibodies Used in Diagnostic Serology" <u>Journal of Immunoassay</u> 16(2):183-197 (1995)				
Examiner: 		Date Considered 10/14/03			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)			Applicant Andya et al.	
			Filing Date 02 Nov 2000	Group 1044 To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
173	Nio et al., "Inhibition of histamine release by synthetic human IgE peptide fragments: structure-activity studies" <u>Peptide Chemistry</u> pps. 203-208 (1989)			
174	Nissim et al., "Mapping of the high affinity Fcε receptor binding site to the third constant region domain of IgE" <u>EMBO Journal</u> 10(1):101-107 (Jan 1991)			
175	Nitta et al., "Preliminary trial of specific targeting therapy against malignant glioma" <u>Lancet</u> 335(8686):368-371 (Feb 17, 1990)			
176	Oi et al., "Chimeric Antibodies" <u>BioTechniques</u> 4(3):214-221 (1986)			
177	Padlan et al., "A model of the Fc of immunoglobulin E" <u>Molecular Immunology</u> 23(10):1063-1075 (1986)			
178	Pearlman et al., "Analysis of Protein Drugs" <u>Peptide and Protein Drug Delivery</u> , Vincent H. L. Lee, Marcel Dekker, Inc., Chapter 6, pps. 247-301 (1991)			
179	Pikal et al., "The Effects of Formulation Variables on the Stability of Freeze-Dried Human Growth Hormone" <u>Pharm. Res.</u> 8:427-436 (1991)			
180	Pikal, M., "Freeze-Drying of Proteins, Part 2, Formulation Selection" <u>BioPharm.</u> 3(9):26-30 (1990)			
181	Platts-Mills et al., "Reduction of Bronchial Hyperreactivity During Prolonged Allergen Avoidance" <u>Lancet</u> 2(8300):675-678 (September 25, 1982)			
182	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)			
183	Qu et al., "Expression and Characterization of a Truncated Murine Fcγ Receptor" <u>Journal of Experimental Medicine</u> 167:1195-1210 (March 1988)			
184	Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" <u>Proc. Natl. Acad. Sci. USA</u> 86(24):10029-10033 (December 1989)			
185	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)			
186	Riske et al., "High Affinity Human IgE Receptor (FcεRI). Analysis of functional Domains of the α-Subunit with Monoclonal Antibodies" <u>Journal of Biological Chemistry</u> 266(17):11245-11251 (June 15, 1991)			
187	Robertson et al., "IgE structure-function relationships defined by sequence directed antibodies induced by synthetic peptides" <u>Molecular Immunology</u> 25(2):103-113 (1988)			
188	Rup et al., "Identification of a Mouse Anti-Rat IgE Monoclonal Antibody, 44.7b, Which Inhibits IgE Binding to RBL Cells" <u>International Archives of Allergy & Applied Immunology</u> 89(4):387-393 (1989)			
189	Saban et al., "Human FcεRI-IgG and Humanized Anti-IgE Monoclonal Antibody MaE11 Block Passive Sensitization of Human and Rhesus Monkey Lung" <u>J. Allergy and Clinical Immunology</u> 94(5):836-843 (November 1994)			
190	"Sandoglobulin" <u>Physicians' Desk Reference</u> pps. 1965-1966 (1991)			
191	Schwarzbaum et al., "Mapping of murine IgE epitopes involved in IgE-Fcε receptor interactions" <u>European Journal of Immunology</u> 19:1015-1023 (1989)			
192	Shaw et al., "Mouse/Human Chimeric Antibodies to a Tumor-Associated Antigen: Biologic Activity of the Four Human IgG Subclasses" <u>J. Nat. Canc. Inst.</u> 80(19):1553-1559 (December 7, 1988)			
Examiner			Date Considered 10/14/00	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0998D3	Serial No. 09/705,457
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Andya et al.	
				Filing Date 02 Nov 2000	Group 1644 To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
193	Shields et al., "Inhibition of Allergic Reactions with Antibodies to IgE" <u>International Archives of Allergy and Immunology</u> 107(1-3):308-312 (May 1995)				
194	"Standardization of Spirometry - 1987 Update" <u>Am. Rev. Respir. Dis.</u> (American Thoracic Society, Medical Section of the American Lung Association) 136:1285-1298 (1987)				
195	Stanworth et al., "Synthetic peptides comprising sequences of the human immunoglobulin E heavy chain capable of releasing histamine" <u>Biochemical Journal</u> 180(3):665-668 (1979)				
196	Stanworth et al., "The use of synthetic peptides in the delineation of immunoglobulin antigenic epitopes and Fc effector functions" <u>Symposium on Synthetic Peptides as Antigens</u> (Ciba Foundation symposium 119), New York:Wiley Vol. 119:226-244 (1986)				
197	Takeda et al., "Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences" <u>Nature</u> 314(6010):452-454 (April 4, 1985)				
198	Takeda et al., "Development of Eosinophilic Airway Inflammation and Airway Hyperresponsiveness in Mast Cell-deficient Mice" <u>Journal of Experimental Medicine</u> 186(3):449-454 (August 1997)				
199	Tao et al., "Studies of aglycosylated chimeric mouse-human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region" <u>Journal of Immunology</u> 143(8):2595-2601 (Oct 15, 1989)				
200	Tepper et al., "The Role of Mast Cells and IgE in Murine Asthma" <u>Asthma Theory to Treatment</u> (Abstract Only) pps. 8 (July 15, 1995)				
201	Tung, A. S., "Production, purification, and characterization of antigen-specific murine monoclonal antibodies of IgE class" <u>Methods in Enzymology</u> , Chapter 6, 92:47-66 (1983)				
202	Vercelli et al., "The B-cell binding site on human immunoglobulin E" <u>Nature</u> 338:649-651 (April 20, 1989)				
203	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)				
204	Wang et al., "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers" <u>J. Parenteral Sci. Tech.</u> (Technical Report No. 10) 42(23):34-326 (1988)				
205	Ward et al., "Theophylline--an Immunomodulatory Role In Asthma?" <u>Am. Rev. Respir. Dis.</u> 147(3):518-523 (1993)				
206	Weetall et al., "Mapping the site of interaction between murine IgE and its high affinity receptor with chimeric Ig" <u>J. Immunol.</u> 145(11):3849-3854 (December 1, 1990)				
207	Weiss et al., "The Interrelationship Among Allergy, Airways Responsiveness, and Asthma" <u>J. Asthma</u> 30(5):329-349 (1993)				
208	Zweiman, B., "The Late-Phase Reaction: Role of IgE, Its Receptor and Cytokines" <u>Current Opinion in Immunology</u> 5:950-955 (1993)				
Examiner 		Date Considered 10/14/03			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					